KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Return on Sales (2016 - 2025)

Historic Return on Sales for Eli Lilly (LLY) over the last 16 years, with Q3 2025 value amounting to 0.32%.

  • Eli Lilly's Return on Sales rose 2300.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year increase of 1100.0%. This contributed to the annual value of 0.24% for FY2024, which is 800.0% up from last year.
  • Per Eli Lilly's latest filing, its Return on Sales stood at 0.32% for Q3 2025, which was up 2300.0% from 0.36% recorded in Q2 2025.
  • In the past 5 years, Eli Lilly's Return on Sales ranged from a high of 0.36% in Q2 2025 and a low of 0.01% during Q3 2023
  • For the 5-year period, Eli Lilly's Return on Sales averaged around 0.22%, with its median value being 0.22% (2021).
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -2200bps in 2023, then skyrocketed by 2300bps in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Return on Sales stood at 0.22% in 2021, then grew by 23bps to 0.27% in 2022, then fell by -12bps to 0.23% in 2023, then soared by 39bps to 0.33% in 2024, then decreased by -3bps to 0.32% in 2025.
  • Its Return on Sales stands at 0.32% for Q3 2025, versus 0.36% for Q2 2025 and 0.22% for Q1 2025.